Biodesix, Inc. (BDSX) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

59.74 k

Shareholding (Mar 2025)

FII

1.40%

Held by 13 FIIs

DII

95.14%

Held by 10 DIIs

Promoter

0.00%

How big is Biodesix, Inc.?

22-Jun-2025

As of Jun 18, Biodesix, Inc. has a market capitalization of 41.70 million, with net sales of 74.47 million and a net profit loss of 40.42 million over the last four quarters. Shareholder's funds are 20.88 million, and total assets are 99.18 million.

What does Biodesix, Inc. do?

22-Jun-2025

Biodesix, Inc. is a U.S. company that develops blood-based diagnostic tests for oncology, classified as a micro-cap with a market cap of $41.70 million. As of March 2025, it reported net sales of $18 million and a net loss of $11 million.

Should I buy, sell or hold Biodesix, Inc.?

22-Jun-2025

Who are in the management team of Biodesix, Inc.?

22-Jun-2025

As of March 2022, the management team of Biodesix, Inc. includes Mr. Robert Cawthorn as Chairman of the Board and Mr. David Brunel as Chief Executive Officer and Director.

Is Biodesix, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Biodesix, Inc. shows a mildly bearish trend with daily moving averages and Bollinger Bands indicating bearish momentum, despite some mildly bullish MACD signals, and has underperformed the S&P 500 with a year-to-date return of -78.01%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate -8.74% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -5.37

Flat results in Jun 25

Risky - Negative EBITDA

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 63 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

23.90

Return on Equity

-3,567.31%

Price to Book

55.69

Revenue and Profits:

Net Sales:

20 Million

(Quarterly Results - Jun 2025)

Net Profit:

-11 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

1.18%

6 Months

42.05%

1 Year

-68.6%

2 Years

-71.34%

3 Years

458.17%

4 Years

-91.88%

5 Years

-97.39%

Biodesix, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Biodesix, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Biodesix, Inc. has changed from sideways to mildly bearish. The current technical stance is bearish, driven by daily moving averages indicating bearish momentum and weekly Bollinger Bands also signaling a bearish trend. While the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall indicators suggest weakness. Additionally, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -78.01% versus the S&P 500's 12.22%....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

28.86%

EBIT Growth (5y)

-8.74%

EBIT to Interest (avg)

-5.37

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

1.82

Sales to Capital Employed (avg)

1.44

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

46.37%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.01

EV to EBIT

-1.99

EV to EBITDA

-2.40

EV to Capital Employed

2.07

EV to Sales

0.87

PEG Ratio

Dividend Yield

ROCE (Latest)

-103.88%

ROE (Latest)

-350.83%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 6 Schemes (3.46%)

Foreign Institutions

Held by 13 Foreign Institutions (1.4%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 11.11% vs -11.76% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -3.60% vs -33.73% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "20.00",
          "val2": "18.00",
          "chgp": "11.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.30",
          "val2": "-7.70",
          "chgp": "-7.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.90",
          "val2": "1.70",
          "chgp": "11.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "-0.50",
          "chgp": "120.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.50",
          "val2": "-11.10",
          "chgp": "-3.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-484.20%",
          "val2": "-504.70%",
          "chgp": "2.05%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 45.21% vs 28.53% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 17.66% vs 20.34% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "71.30",
          "val2": "49.10",
          "chgp": "45.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-28.80",
          "val2": "-35.80",
          "chgp": "19.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.10",
          "val2": "9.50",
          "chgp": "-25.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.60",
          "val2": "-1.30",
          "chgp": "-23.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-42.90",
          "val2": "-52.10",
          "chgp": "17.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-480.30%",
          "val2": "-841.30%",
          "chgp": "36.10%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

20.00

18.00

11.11%

Operating Profit (PBDIT) excl Other Income

-8.30

-7.70

-7.79%

Interest

1.90

1.70

11.76%

Exceptional Items

0.10

-0.50

120.00%

Consolidate Net Profit

-11.50

-11.10

-3.60%

Operating Profit Margin (Excl OI)

-484.20%

-504.70%

2.05%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 11.11% vs -11.76% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -3.60% vs -33.73% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

71.30

49.10

45.21%

Operating Profit (PBDIT) excl Other Income

-28.80

-35.80

19.55%

Interest

7.10

9.50

-25.26%

Exceptional Items

-1.60

-1.30

-23.08%

Consolidate Net Profit

-42.90

-52.10

17.66%

Operating Profit Margin (Excl OI)

-480.30%

-841.30%

36.10%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 45.21% vs 28.53% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 17.66% vs 20.34% in Dec 2023

All Annual Results

Company CV

About Biodesix, Inc.

Biodesix, Inc.

Pharmaceuticals & Biotechnology

Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.

Company Coordinates

Company Details

2970 Wilderness Place, Suite 100 , BOULDER CO : 80301

Tel: 1 303 4170500

https://www.biodesix.com/

Registrar Details

Biodesix, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Biodesix, Inc.?

Watch in Real-Time

What does Biodesix, Inc. do?

Should I buy, sell or hold Biodesix, Inc.?

Who are in the management team of Biodesix, Inc.?

Is Biodesix, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Flat results in Jun 25

Risky - Negative EBITDA

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Biodesix, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Biodesix, Inc.

Company Coordinates